+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific Antibody Drug Conjugates Market - Forecasts from 2022 to 2027

  • PDF Icon

    Report

  • 95 Pages
  • May 2022
  • Region: Asia Pacific
  • Knowledge Sourcing Intelligence LLP
  • ID: 5602477
The rapidly increasing number of cancer cases in the Asia Pacific region is one of the prominent reasons anticipated to drive the growth of the antibody-drug conjugates market. Furthermore, drug developers are increasingly investing in antibody-drug conjugates, looking at the immense opportunities in the market, which is projected to supplement the market growth in the coming years. The growing geriatric population in the region is another prominent factor anticipated to affect the market growth of antibody-drug conjugates positively during the forecast period. According to data from the World Bank, the population of people aged 65 years and above in East Asia and the Pacific has increased from 184.287 million in 2010 to 273.553 million in 2020.



The COVID-19 pandemic had a negative impact on the Asia Pacific antibody-drug conjugates market. In Asian countries like India, many COVID-19 cases were seen, which consequently shifted the focus of the healthcare sector towards COVID-19 patients. Access to hospitals was reduced for non-COVID patients. As a result, a decrease in the diagnosis of cancers was seen, which resulted in decreased demand for antibody-drug conjugates in the region. As a result, lower market growth was seen than initially expected.

Growing cases of cancer


Cancer cases have been increasing rapidly in the Asia Pacific region. As antibody-drug conjugates are used in cancer treatment, their demand are expected to surge with the projected rise of cancer cases in the coming years. According to the International Agency for Research on Cancer (IARC), the new cancer cases in India are projected to increase from 1.324 million in 2020 to 2.086 million in 2040, witnessing an increase of more than 57%. In China, the number of new cancer cases is projected to increase by around 50%, from 4.569 million in 2020 to 6.846 million in 2040. Indonesia is another country witnessing a rapid rise in its cancer cases and is projected to witness a massive jump in its cancer cases in the future. IARC data shows that the new cancer cases in Indonesia are anticipated to rise by more than 62% between 2020 and 2040.

Rising investments to develop antibody-drug conjugates


An increased number of investments are being seen for developing antibody-drug conjugates, which is expected to boost the market growth during the assessment period. For instance, in June 2018, WuXi Biologics, a China-based company, initiated the construction of a $20 million worth of antibody-drug conjugates center near Shanghai, China. In May 2021, Suzhou Medilink Therapeutics (Medilink) raised $50 million to accelerate the development of antibody-drug conjugates for cancer. Increased investments can be seen in other countries in the Asia Pacific as well, including India and Japan, which is anticipated to have a positive impact on the market growth.

Segmentation


By Technology

  • Cleavable Linker
  • Non-cleavable Linker
  • Linkerless

By Product Type

  • Adcetris
  • Kadcyla
  • Others

By Target

  • CD 30
  • CD 22
  • HER 2
  • Others

By Geography

  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others
Frequently Asked Questions about the Asian Pacific Antibody Drug Conjugates Market

What is the estimated value of the Asian Pacific Antibody Drug Conjugates Market?

The Asian Pacific Antibody Drug Conjugates Market was estimated to be valued at $3359.87 million in 2020.

What is the growth rate of the Asian Pacific Antibody Drug Conjugates Market?

The growth rate of the Asian Pacific Antibody Drug Conjugates Market is 27.6%, with an estimated value of $18523.74 million by 2027.

What is the forecasted size of the Asian Pacific Antibody Drug Conjugates Market?

The Asian Pacific Antibody Drug Conjugates Market is estimated to be worth $18523.74 million by 2027.

Who are the key companies in the Asian Pacific Antibody Drug Conjugates Market?

Key companies in the Asian Pacific Antibody Drug Conjugates Market include Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, F. Hoffmann, La Roche Ltd., ImmunoGen Inc., Pfizer Inc. and Synthon Holding B.V..

Table of Contents

1. Introduction
1.1. Market Definition
1.2. Market Segmentation
2. Research Methodology
2.1. Research Data
2.2. Assumptions
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of End-Users
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Asia Pacific Antibody-Drug Conjugates Market Analysis, by Technology
5.1. Introduction
5.2. Cleavable Linker
5.3. Non-cleavable Linker
5.4. Linkerless
6. Asia Pacific Antibody-Drug Conjugates Market Analysis, by Product Type
6.1. Introduction
6.2. Adcetris
6.3. Kadcyla
6.4. Others
7. Asia Pacific Antibody-Drug Conjugates Market Analysis, by Target
7.1. Introduction
7.2. CD 30
7.3. CD 22
7.4. HER 2
7.5. Others
8. Asia Pacific Antibody-Drug Conjugates Market Analysis, by Geography
8.1. Introduction
8.2. China
8.3. India
8.4. Japan
8.5. South Korea
8.6. Taiwan
8.7. Thailand
8.8. Indonesia
8.9. Others
9. Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. Company Profiles
10.1. Daiichi Sankyo Company, Limited
10.2. Eisai Co., Ltd.
10.3. Takeda Pharmaceutical Company Limited
10.4. F. Hoffmann-La Roche Ltd.
10.5. ImmunoGen Inc.
10.6. Pfizer Inc.
10.7. Lonza
10.8. Synthon Holding B.V.

Companies Mentioned

  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd.
  • ImmunoGen Inc.
  • Pfizer Inc.
  • Lonza
  • Synthon Holding B.V.